ITER Organization and Principality of Monaco sign Partnership Agreement, Monaco
Agreement that sets up five Postdoctoral Fellowships and the establishment of an annual International Conference on ITER related research. The Agreement was signed by his Excellency, the Minister of the Principality of Monaco, Monsieur Jean Paul Proust and the Director General of the ITER Organization, Kaname Ikeda, in the presence of His Serene Highness Prince Albert II.
This Partnership Agreement underlines the Principality of Monaco’s historical interest in nature preservation and its commitment to create, together with the International Fusion Community, a new energy source. “It is important to make the public and the principality’s economic actors become aware of the ITER project and the stakes it holds for our planet’s future”, Monsieur Jean Paul Proust said.
The Partnership Arrangement includes a contribution by the Principality of Monaco of 5.5 Million Euro for a ten year period, of which 150.000 € are to be dedicated to scientific conferences, and 400.000 € to Postdoctoral Fellowships each year. These Postdoctoral Fellowships shall enable five young scientists from the seven ITER Member countries or from the Principality of Monaco to be trained over two years in research areas related to the ITER project.
The Partnership Arrangement also foresees the organisation of an annual International Conference on scientific and technical subjects related to the ITER project that will take place in Monaco. In addition, the Principality of Monaco will host scientific meetings related to the ITER project or the ITER Council.
The arrangement enters into force immediately and will be concluded for a ten year period.
All latest news from the category: Science Education
Prostate cancer organoids open path to precision oncology
A multi-institutional team of investigators led by bioengineer Ankur Singh has developed research tools that shed new light on a virtually untreatable form of prostate cancer, opening a pathway that may lead…
Experimental compound counters diabetic complications
An experimental compound reduced complications of type 1 and type 2 diabetes in mice – not by lowering blood sugar – but by countering its consequences: cell death, inflammation, and…